Carol L Shields, Rhea Suribhatla, Mark Romero, Christin Ealer, Rolika Bansal, Jacqueline Emrich, Lydia Komarnicky-Kocher, Sara E Lally
{"title":"组织胶辅助斑块放疗治疗伴有巩膜变薄的脉络膜肿瘤。","authors":"Carol L Shields, Rhea Suribhatla, Mark Romero, Christin Ealer, Rolika Bansal, Jacqueline Emrich, Lydia Komarnicky-Kocher, Sara E Lally","doi":"10.1097/IAE.0000000000004355","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate tissue glue-assisted plaque placement regarding accuracy, stability, and longer-term outcomes for choroidal tumors with scleral thinning.</p><p><strong>Methods: </strong>All patients with tissue glue-assisted plaque radiotherapy at a single ocular oncology center were evaluated for patient demographics, tumor features, surgical details, tumor response, and glue-related complications.</p><p><strong>Results: </strong>There were 13 patients (mean age 72 years) treated with tissue glue-assisted plaque radiotherapy for choroidal melanoma (n=12) or choroidal metastasis (n=1). At presentation, the tumor was mean 4.3 mm to the optic disc and 2.0 mm to the foveola with mean basal diameter of 9.5 mm and thickness of 4.2 mm. In all cases, the tissue glue-assistance was employed due to extreme scleral thinning in the bed of proposed radiation. The plaque size was 15 mm (n=5), 18 mm (n=7), or 20 mm (n=1). At application, there was no immediate glue hypersensitivity, ultrasonography confirmed accuracy of placement, and the glue remained adherent for the entire treatment duration (mean 113 hours) with stable plaque location at removal. At removal, the plaque-glue composite was peeled off the globe without need for glue dissolvent and without scleral disruption. At 12 months mean melanoma thickness (2.7 mm, regression 36%). There were no conjunctival, corneal, or scleral complications.</p><p><strong>Conclusion: </strong>Tissue glue-assisted plaque radiotherapy is safe and effective for treatment of choroidal tumors with thin sclera.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tissue Glue-Assisted Plaque Radiotherapy for Choroidal Tumors with Scleral Thinning.\",\"authors\":\"Carol L Shields, Rhea Suribhatla, Mark Romero, Christin Ealer, Rolika Bansal, Jacqueline Emrich, Lydia Komarnicky-Kocher, Sara E Lally\",\"doi\":\"10.1097/IAE.0000000000004355\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate tissue glue-assisted plaque placement regarding accuracy, stability, and longer-term outcomes for choroidal tumors with scleral thinning.</p><p><strong>Methods: </strong>All patients with tissue glue-assisted plaque radiotherapy at a single ocular oncology center were evaluated for patient demographics, tumor features, surgical details, tumor response, and glue-related complications.</p><p><strong>Results: </strong>There were 13 patients (mean age 72 years) treated with tissue glue-assisted plaque radiotherapy for choroidal melanoma (n=12) or choroidal metastasis (n=1). At presentation, the tumor was mean 4.3 mm to the optic disc and 2.0 mm to the foveola with mean basal diameter of 9.5 mm and thickness of 4.2 mm. In all cases, the tissue glue-assistance was employed due to extreme scleral thinning in the bed of proposed radiation. The plaque size was 15 mm (n=5), 18 mm (n=7), or 20 mm (n=1). At application, there was no immediate glue hypersensitivity, ultrasonography confirmed accuracy of placement, and the glue remained adherent for the entire treatment duration (mean 113 hours) with stable plaque location at removal. At removal, the plaque-glue composite was peeled off the globe without need for glue dissolvent and without scleral disruption. At 12 months mean melanoma thickness (2.7 mm, regression 36%). There were no conjunctival, corneal, or scleral complications.</p><p><strong>Conclusion: </strong>Tissue glue-assisted plaque radiotherapy is safe and effective for treatment of choroidal tumors with thin sclera.</p>\",\"PeriodicalId\":54486,\"journal\":{\"name\":\"Retina-The Journal of Retinal and Vitreous Diseases\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-11-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Retina-The Journal of Retinal and Vitreous Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/IAE.0000000000004355\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004355","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:评估组织胶辅助斑块放置对巩膜变薄脉络膜肿瘤的准确性、稳定性和长期预后的影响。方法:在单个眼科肿瘤中心对所有接受组织胶辅助斑块放疗的患者进行患者人口统计学、肿瘤特征、手术细节、肿瘤反应和胶相关并发症的评估。结果:13例患者(平均年龄72岁)接受组织胶辅助斑块放疗治疗脉络膜黑色素瘤(n=12)或脉络膜转移(n=1)。发病时,肿瘤距视盘平均4.3 mm,距中央凹平均2.0 mm,平均基底直径9.5 mm,厚度4.2 mm。在所有病例中,由于建议的放射床的巩膜极度变薄,使用组织胶辅助。斑块大小分别为15 mm (n=5)、18 mm (n=7)和20 mm (n=1)。在应用时,没有立即出现胶水过敏,超声检查证实了放置的准确性,并且胶水在整个治疗期间(平均113小时)保持粘附,并且在去除斑块时稳定定位。在移除时,斑块-胶复合材料被从球体上剥离,不需要胶水溶剂,也没有巩膜断裂。12个月时黑色素瘤平均厚度(2.7 mm,回归36%)。无结膜、角膜或巩膜并发症。结论:组织胶辅助斑块放疗治疗巩膜薄的脉络膜肿瘤安全有效。
Tissue Glue-Assisted Plaque Radiotherapy for Choroidal Tumors with Scleral Thinning.
Purpose: To evaluate tissue glue-assisted plaque placement regarding accuracy, stability, and longer-term outcomes for choroidal tumors with scleral thinning.
Methods: All patients with tissue glue-assisted plaque radiotherapy at a single ocular oncology center were evaluated for patient demographics, tumor features, surgical details, tumor response, and glue-related complications.
Results: There were 13 patients (mean age 72 years) treated with tissue glue-assisted plaque radiotherapy for choroidal melanoma (n=12) or choroidal metastasis (n=1). At presentation, the tumor was mean 4.3 mm to the optic disc and 2.0 mm to the foveola with mean basal diameter of 9.5 mm and thickness of 4.2 mm. In all cases, the tissue glue-assistance was employed due to extreme scleral thinning in the bed of proposed radiation. The plaque size was 15 mm (n=5), 18 mm (n=7), or 20 mm (n=1). At application, there was no immediate glue hypersensitivity, ultrasonography confirmed accuracy of placement, and the glue remained adherent for the entire treatment duration (mean 113 hours) with stable plaque location at removal. At removal, the plaque-glue composite was peeled off the globe without need for glue dissolvent and without scleral disruption. At 12 months mean melanoma thickness (2.7 mm, regression 36%). There were no conjunctival, corneal, or scleral complications.
Conclusion: Tissue glue-assisted plaque radiotherapy is safe and effective for treatment of choroidal tumors with thin sclera.
期刊介绍:
RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice.
In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color.
Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.